The Impact of the COVID-19 Pandemic on Tobacco Treatment Program Implementation at National Cancer Institute-Designated Cancer Centers.


Journal

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
ISSN: 1469-994X
Titre abrégé: Nicotine Tob Res
Pays: England
ID NLM: 9815751

Informations de publication

Date de publication:
05 01 2023
Historique:
received: 30 11 2021
revised: 17 05 2022
accepted: 27 06 2022
pubmed: 2 7 2022
medline: 11 1 2023
entrez: 1 7 2022
Statut: ppublish

Résumé

The COVID-19 pandemic disrupted cancer screening and treatment delivery, but COVID-19's impact on tobacco cessation treatment for cancer patients who smoke has not been widely explored. We conducted a sequential cross-sectional analysis of data collected from 34 National Cancer Institute (NCI)-designated cancer centers participating in NCI's Cancer Center Cessation Initiative (C3I), across three reporting periods: one prior to COVID-19 (January-June 2019) and two during the pandemic (January-June 2020, January-June 2021). Using McNemar's Test of Homogeneity, we assessed changes in services offered and implementation activities over time. The proportion of centers offering remote treatment services increased each year for Quitline referrals (56%, 68%, and 91%; p = .000), telephone counseling (59%, 79%, and 94%; p = .002), and referrals to Smokefree TXT (27%, 47%, and 56%; p = .006). Centers offering video-based counseling increased from 2020 to 2021 (18% to 59%; p = .006), Fewer than 10% of centers reported laying off tobacco treatment staff. Compared to early 2020, in 2021 C3I centers reported improvements in their ability to maintain staff and clinician morale, refer to external treatment services, train providers to deliver tobacco treatment, and modify clinical workflows. The COVID-19 pandemic necessitated a rapid transition to new telehealth program delivery of tobacco treatment for patients with cancer. C3I cancer centers adjusted rapidly to challenges presented by the pandemic, with improvements reported in staff morale and ability to train providers, refer patients to tobacco treatment, and modify clinical workflows. These factors enabled C3I centers to sustain evidence-based tobacco treatment implementation during and beyond the COVID-19 pandemic. This work describes how NCI-designated cancer centers participating in the Cancer Center Cessation Initiative (C3I) adapted to challenges to sustain evidence-based tobacco use treatment programs during the COVID-19 pandemic. This work offers a model for resilience and rapid transition to remote tobacco treatment services delivery and proposes a policy and research agenda for telehealth services as an approach to sustaining evidence-based tobacco treatment programs.

Identifiants

pubmed: 35778237
pii: 6626063
doi: 10.1093/ntr/ntac160
pmc: PMC9384385
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

345-349

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco.

Auteurs

Sarah D Hohl (SD)

Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.

Kimberly A Shoenbill (KA)

Department of Family Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA.

Kathryn L Taylor (KL)

Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Cancer Prevention and Control Program, Washington, DC, USA.

Mara Minion (M)

Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.

Gleneara E Bates-Pappas (GE)

Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Rashelle B Hayes (RB)

Department of Psychiatry, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.

Margaret B Nolan (MB)

Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Center for Tobacco Research and Intervention, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

Vani N Simmons (VN)

Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.

Michael B Steinberg (MB)

Center for Tobacco Studies, Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

Elyse R Park (ER)

Department of Psychiatry, Massachusetts General Hospital (MGH), Boston, MA, USA.

Kimlin Ashing (K)

Department of Population Sciences, Center of Community Alliance for Research & Education, City of Hope National Medical Center, Duarte, CA, USA.

Diane Beneventi (D)

Tobacco Research and Treatment Program, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.

Lisa Sanderson Cox (L)

Cancer Prevention and Control, University of Kansas School of Medicine, University of Kansas Cancer Center, Kansas City, KS, USA.

Adam O Goldstein (AO)

Department of Family Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA.

Andrea King (A)

Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA.

Chris Kotsen (C)

Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Cary A Presant (CA)

Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.

Scott E Sherman (SE)

Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA.

Christine E Sheffer (CE)

Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Graham W Warren (GW)

Department of Radiation Oncology, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA.
Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA.

Robert T Adsit (RT)

Center for Tobacco Research and Intervention, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

Jennifer E Bird (JE)

Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.

Heather D'Angelo (H)

Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.

Michael C Fiore (MC)

Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.
Center for Tobacco Research and Intervention, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

Claire Van Thanh Nguyen (C)

Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.

Danielle Pauk (D)

Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.

Betsy Rolland (B)

Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.
Institute for Clinical and Translational Research, University of Wisconsin-Madison, Madison, WI, USA.

Nancy A Rigotti (NA)

Department of Medicine, Division of General Internal Medicine and Mongan Institute, Tobacco Research and Treatment Center, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH